Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Head-to-Head: which biologic works better for tough psoriatic arthritis?

NCT ID NCT04632927

Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested two biologic drugs, secukinumab and ustekinumab, in 119 adults with active psoriatic arthritis who had not responded to or could not tolerate TNFα-inhibitor treatment. The main goal was to see which drug better improved physical function over 28 weeks. Researchers also looked at skin clearance and other outcomes. The trial is complete, and results are available.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Secukinumab (a biologic drug) and Ustekinumab (a biologic drug)
What this could lead to
If secukinumab works better than ustekinumab, it could offer a new treatment option for people with psoriatic arthritis who have not responded to other therapies.
What could go wrong
This is a completed Phase 3 trial with 119 participants, so results are more reliable than early-phase studies. However, individual responses vary, and both drugs have known side effects like increased infection risk.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

119 people

The number who actually took part.

Started

Dec 2020

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 99 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Key Inclusion Criteria: * Diagnosis of PsA as classified by CASPAR criteria for at least 6 months before randomization. * Active PsA at baseline defined as ≥ 3 tender joints out of 68 and ≥ 3 swollen joints out of 66 (dactylitis of a digit counts as one joint each). * Inadequate response or intolerance to previous or current treatment with at least one TNFα inhibitor * Inadequate response or intolerance to conventional disease modifying anti-rheumatic drugs (cDMARDs) * Diagnosis of active plaque psoriasis, with at least one psoriatic plaque of ≥ 2 cm diameter and/or nail changes consistent with psoriasis and/or documented history of plaque psoriasis. * Rheumatoid factor (RF) and anti-cyclic citrullinated peptide (CCP) antibodies negative at screening. Key Exclusion Criteria: * Pregnant or nursing women, * Previous exposure to secukinumab, ustekinumab or any other biologic drug directly targeting IL-17, IL-17 receptor, IL-12 or IL-23. * Patients for whom the use of secukinumab or ustekinumab is contraindicated. * Use of any other investigational drug. Previous treatment with any cell-depleting therapies including but not limited to anti-CD20 or investigational agents * Evidence of ongoing infectious or malignant process * Subjects receiving high potency opioid analgesics * Ongoing use of prohibited psoriasis treatments/medications Other protocol-defined inclusion/exclusion criteria may apply

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Psoriatic arthritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

psoriatic arthritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Psoriatic arthritis

Contacts and locations

Locations

  • Novartis Investigative Site

    Rendsburg, Schleswig-Holstein, 24768, Germany

  • Novartis Investigative Site

    Aachen, 52074, Germany

  • Novartis Investigative Site

    Bad Bentheim, 48455, Germany

  • Novartis Investigative Site

    Bad Doberan, 18209, Germany

  • Novartis Investigative Site

    Berlin, 12435, Germany

  • Novartis Investigative Site

    Berlin, 13125, Germany

  • Novartis Investigative Site

    Berlin, 13353, Germany

  • Novartis Investigative Site

    Bochum, 44791, Germany

  • Novartis Investigative Site

    Cologne, 50937, Germany

  • Novartis Investigative Site

    Cologne, 51149, Germany

  • Novartis Investigative Site

    Cottbus, 03042, Germany

  • Novartis Investigative Site

    Dresden, 01067, Germany

  • Novartis Investigative Site

    Dresden, 01307, Germany

  • Novartis Investigative Site

    Ehringshausen, 35630, Germany

  • Novartis Investigative Site

    Erlangen, 91056, Germany

  • Novartis Investigative Site

    Frankfurt, 60590, Germany

  • Novartis Investigative Site

    Freiburg im Breisgau, 79106, Germany

  • Novartis Investigative Site

    Gommern, 39245, Germany

  • Novartis Investigative Site

    Göttingen, 37075, Germany

  • Novartis Investigative Site

    Hamburg, 22391, Germany

  • Novartis Investigative Site

    Herne, 44649, Germany

  • Novartis Investigative Site

    Leipzig, 04103, Germany

  • Novartis Investigative Site

    Magdeburg, 39104, Germany

  • Novartis Investigative Site

    Magdeburg, 39110, Germany

  • Novartis Investigative Site

    Mainz, 55131, Germany

  • Novartis Investigative Site

    München, 81541, Germany

  • Novartis Investigative Site

    Planegg, 82152, Germany

  • Novartis Investigative Site

    Ratingen, 40878, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.